Universal Beteiligungs und Servicegesellschaft mbH Acquires New Position in Immunome, Inc. $IMNM

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake of 170,002 shares in Immunome (NASDAQ:IMNM) during Q4, valued at about $3.65 million and representing roughly 0.19% of the company.
• CFO Max Rosett sold 65,000 shares on April 2 (and insider Jack Higgins sold 9,438), transactions executed under pre‑arranged Rule 10b5‑1 plans; insiders have sold 139,438 shares over the last 90 days and now own 7.69% of the stock.
• The stock carries a consensus rating of "Moderate Buy" (10 Buys, 1 Sell) with a $33.45 average price target, while IMNM trades near $22.95, has a $2.6 billion market cap, and recently missed EPS estimates.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 170,002 shares of the company's stock, valued at approximately $3,652,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.19% of Immunome at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Immunome by 8.1% in the third quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company's stock valued at $57,304,000 after buying an additional 368,674 shares during the period. Principal Financial Group Inc. lifted its holdings in Immunome by 222.3% in the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company's stock valued at $12,939,000 after buying an additional 762,147 shares during the period. Polar Capital Holdings Plc lifted its holdings in Immunome by 5.9% in the third quarter. Polar Capital Holdings Plc now owns 1,058,776 shares of the company's stock valued at $12,398,000 after buying an additional 58,776 shares during the period. Candriam S.C.A. lifted its holdings in Immunome by 170.2% in the third quarter. Candriam S.C.A. now owns 859,527 shares of the company's stock valued at $10,065,000 after buying an additional 541,441 shares during the period. Finally, TD Asset Management Inc lifted its holdings in Immunome by 15.8% in the third quarter. TD Asset Management Inc now owns 701,280 shares of the company's stock valued at $8,212,000 after buying an additional 95,750 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Max Rosett sold 65,000 shares of the firm's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $21.92, for a total transaction of $1,424,800.00. Following the sale, the chief financial officer directly owned 54,037 shares in the company, valued at $1,184,491.04. This trade represents a 54.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 9,438 shares of the firm's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the sale, the insider owned 22,000 shares in the company, valued at approximately $476,080. The trade was a 30.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 139,438 shares of company stock worth $2,964,664 over the last ninety days. Company insiders own 7.69% of the company's stock.

Immunome Stock Performance

IMNM opened at $22.95 on Thursday. The firm's fifty day moving average is $21.86 and its two-hundred day moving average is $20.72. The firm has a market cap of $2.60 billion, a PE ratio of -9.48 and a beta of 2.13. Immunome, Inc. has a twelve month low of $7.15 and a twelve month high of $27.65.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Equities analysts forecast that Immunome, Inc. will post -2.5 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. HC Wainwright assumed coverage on shares of Immunome in a report on Thursday, February 12th. They issued a "buy" rating and a $40.00 target price on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunome in a report on Tuesday, April 21st. Craig Hallum increased their target price on shares of Immunome from $33.00 to $36.00 and gave the stock a "buy" rating in a report on Wednesday, March 4th. Wall Street Zen lowered shares of Immunome from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Finally, Stephens cut their target price on shares of Immunome from $33.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, March 4th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Immunome currently has an average rating of "Moderate Buy" and a consensus price target of $33.45.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.